相关临床试验
24
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1990
进行中（未招募）
1
4.2%
已完成
17
70.8%
招募中
1
4.2%
终止
3
12.5%
Unknown
1
4.2%
撤回
1
4.2%
暂无批准数据
- The EPIC clinical trial conducted by University Hospitals Bristol and Weston NHS Foundation Trust demonstrated that immunotherapy combined with chemotherapy extended predicted lifespans in more than half of advanced penile cancer patients. - Among patients showing clinical benefit, predicted lifespans increased to 15 months on average, with more than 60% of participants experiencing clinical benefit from the treatment. - The trial's success has prompted plans for a new study to administer immunotherapy at earlier disease stages, potentially improving cure rates for this rare cancer. - Despite the promising results, the immunotherapy treatment remains unavailable on the NHS, with researchers applying to the Cancer Drugs Fund for coverage.
- Phase 2 EPIC trial demonstrates 62.1% clinical benefit rate at 12 weeks for cemiplimab combined with platinum-based chemotherapy in advanced penile carcinoma patients. - Treatment achieved median progression-free survival of 6.2 months and overall survival of 15.5 months, with 51.7% objective response rate at 12 weeks. - Safety profile remained consistent with previous data, with manageable adverse events and no new safety signals identified in the 29-patient study.
